Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Urological devices incorporating collagen inhibitors

a technology of collagen inhibitors and urological devices, applied in the field of medical devices, can solve the problems of vexing urologists urethral or ureteral strictures, and high failure rate of techniques, and achieve the effect of preventing or reducing the formation of capsules

Inactive Publication Date: 2009-01-29
WAKE FOREST UNIV HEALTH SCI INC
View PDF54 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010]Methods of preventing or reducing capsule formation in a subject undergoing implantation of a medical device (e.g., breast implants, pacemakers, orthopedic joint prosthetics, etc.) are provided, including providing a collagen inhibitor on or in said medical device.

Problems solved by technology

Luminal strictures, such as urethral or ureteral strictures, represent a vexing problem for urologists.
Urethral strictures are commonly treated with dilation and / or incision followed by stenting, but such techniques have suffered from high failure rates.
Unfortunately, wound healing cannot be well controlled, and the new incision heals via the deposition of type-I collagen, which may contract, causing a high rate of stricture recurrence.
However, oral administration or administration by injection is not ideal.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Urological devices incorporating collagen inhibitors
  • Urological devices incorporating collagen inhibitors
  • Urological devices incorporating collagen inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Coated Ureteral and Urethral Catheter Material

[0118]A collagen inhibitor coated catheter could be inserted following stricture incision, preventing recurrence by delivering a small amount of collagen inhibitor to the specific area of interest.

[0119]Halofuginone bromide (HF) is a substance known to be a potent Collagen Type I inhibitor, and previous studies have demonstrated that oral and local halofuginone administration can prevent luminal strictures, including urethral strictures. However, no previous studies have demonstrated the ability of HF coated stents to prevent urethral stricture formation. The objectives of this study were to successfully coat urethral stents with HF, and then to test whether HF coated stents could prevent spongiofibrosis in a small animal model of urethral stricture disease.

[0120]Halocur® (Oral Halofuginone. 0.5 mg / mL) was obtained from Intervet International BV of Norway. The rat stents were made of silicone tubing (0.30 mm×0.64 mm) from SMI, while the ...

example 2

Human Testing

[0129]Ten male patients with comparable urethral strictures amenable to treatment by DVIU therapy (<2 cm length) are recruited and divided into 2 treatment groups. Group A (5 men) are treated with DVIU and then stented for 4 days with a silicone urethral Foley catheter. Group B (5 men) are treated with DVIU and then stented for 4 days with a type-I collagen inhibitor coated silicone catheter.

[0130]The type-I collagen inhibitor coated silicone urethral catheter consists of a Bard All-Silicone 16 french Foley catheter (already in widespread use in humans), coated with the specific type-I collagen inhibitor halofuginone, approximately 0.375 mg of halofuginone in the form of the solution Halocur. The catheters used will be Bard 16 french 100% silicone Foley catheters, purchased for hospital use through the usual vendors, and therefore packaged sterilely. The catheter will then be removed from its packaging and coated with the drug Halocur (0.5 mg / ml halofuginone solution) a...

example 3

Catheter Coating

[0133]The following is a list of ureteral and urethral catheter material that we have demonstrated the ability to coat with halofuginone using imaging studies (microscopic and gross), weight changes, and elution data over 4 days:

[0134]General device material: Silicone, Silastic, Latex, Polyurethane, Nitinol, PLGA.

[0135]Boston Scientific products: Percuflex stents, Flexima stents, Pebax material.

[0136]Cook stents: Polyurethane, Sof-flex, AQ stents, Endo-sof stents.

[0137]Bard stents: Polyurethane, Latex, Woven stents, Lubricath Foley, Inlay stent, Elastomer coated catheters, Silver coated catheters.

[0138]The stents were coated as follows: 1. Wet stent with PBS and cover with PBS soaked gauze and microwave for 40 sec; 2. Dip stent in 2% PLGA-COOH to cool; 3. Dry under hood; 4. Cover with PBS soaked gauze and microwave (or plasma) for 30 sec; 5. Coat stent with halofuginone (immerse) and freeze in liquid nitrogen and lyophilize overnight; 6. Weight should be measured bef...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
period of timeaaaaaaaaaa
period of timeaaaaaaaaaa
Login to View More

Abstract

Provided herein are implantable or insertable biomedical devices comprising a substrate and a collagen inhibitor on or in said substrate, and methods of treatment using the same. In some embodiments, the device is a urethral, ureteral, or nephroureteral catheter or stent. Kits comprising the same are also provided.

Description

RELATED APPLICATIONS[0001]This application is a continuation-in-part of application Ser. No. 11 / 948,335, filed Nov. 30, 2007, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60 / 868,217, filed Dec. 1, 2006, the disclosure of each of which is incorporated by reference herein in its entirety.[0002]This application is related to application Ser. No. 11 / 948,294, filed Nov. 30, 2007, and application Ser. No. ______, filed May 30, 2008, the disclosures of each of which is incorporated by reference herein in its entirety.FIELD OF THE INVENTION[0003]The present invention concerns medical devices, including implantable devices such as catheters and stents.BACKGROUND OF THE INVENTION[0004]Luminal strictures, such as urethral or ureteral strictures, represent a vexing problem for urologists. Urethral strictures result from spongiofibrosis, most of which is composed of type I collagen, and are due to the imbalance of collagen formation and destruction following urethral ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61F2/04A61K31/704
CPCA61F2/02A61L27/54A61L2300/432A61L31/16A61L29/16A61L15/44Y10S606/907A61K31/517A61P41/00A61K9/0034A61F2/82A61F2/042A61B17/04A61L17/00A61K9/146A61K9/7007
Inventor HODGES, STEVE J.
Owner WAKE FOREST UNIV HEALTH SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com